Sarepta Therapeutics, Inc. (SRPT) P/E Ratio History
UndervaluedTrading at 127.9x vs 5Y avg 598.1x · 50th percentile · Below historical baseline · Data 2024–2024
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Sarepta Therapeutics, Inc. (SRPT) trades at a price-to-earnings ratio of 127.9x, with a stock price of $17.82 and trailing twelve-month earnings per share of $0.14.
The current P/E is 79% below its 5-year average of 598.1x. Over the past five years, SRPT's P/E has ranged from a low of 53.6x to a high of 1849.4x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, SRPT trades at a 420% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, SRPT commands a significant premium over the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SRPT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SRPT Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SRPT P/E vs Peers
RNA Medicines peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $21B | 7.9Lowest | -Best | +207%Best | |
| $9B | 41.2 | -Best | +128% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SRPT Historical P/E Data (2024–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | - | $121.59 | $2.27 | 53.6x | -91% |
| FY2024 Q3 | Sep 30 2024 | $124.89 | $1.20 | 104.1x | -83% |
| FY2024 Q2 | Jun 30 2024 | $158.00 | $0.41 | 385.4x | -36% |
| FY2024 Q1 | Mar 31 2024 | $129.46 | $0.07 | 1849.4x | +209% |
Average P/E for displayed period: 598.1x
SRPT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SRPT — Frequently Asked Questions
Quick answers to the most common questions about buying SRPT stock.
What is SRPT's P/E ratio?
Sarepta Therapeutics, Inc. (SRPT) trailing twelve-month P/E ratio is 127.9x, based on TTM diluted EPS of $0.14. The 5-year average P/E is 598.1x and the historical range spans 53.6x to 1849.4x.
Is SRPT stock overvalued or undervalued?
SRPT trades at 127.9x P/E, below its 5-year average of 598.1x. At the 50th percentile of its historical range (53.6x–1849.4x), the stock is priced at a discount to its own history.
Is SRPT stock expensive?
No, SRPT is not expensive on a historical basis. The current P/E of 127.9x is below the 5-year average of 598.1x and sits at the 50th percentile of its valuation range.
What is SRPT's historical P/E range?
Over the past 5 years, SRPT's P/E ratio has ranged from 53.6x to 1849.4x, with a median of 385.4x and an average of 598.1x. The current P/E of 127.9x places the stock at the 50th percentile of this range. Full historical data spans 2024–2024.
How does SRPT's P/E compare to the S&P 500?
SRPT trades at 127.9x P/E versus the S&P 500 median of 21.8x. The 487% premium to the market typically reflects higher expected earnings growth or quality.
How does SRPT's valuation compare to Healthcare peers?
Sarepta Therapeutics, Inc. P/E of 127.9x compares to the Healthcare sector median of 24.6x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SRPT's PEG ratio?
SRPT PEG ratio is N/A, based on a P/E of 127.9x and EPS growth of -404.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SRPT's earnings yield?
SRPT earnings yield is 0.78%, the inverse of its 127.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.